![Christopher Landeg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Landeg
Chief Operating Officer at Quotient Sciences (Reading) Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gordon Cameron | M | 58 |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Mark Egerton | M | 61 |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Alan Browning MacKay | M | 62 |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Michael Irvine Mortimer | M | 64 |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Joseph Thomis | M | 78 |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Syed Ehtisham Abidi | M | - |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Shahid Raza | M | - |
Quotient Sciences (Reading) Ltd.
![]() Quotient Sciences (Reading) Ltd. Pharmaceuticals: MajorHealth Technology Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 7 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher Landeg
- Personal Network